- Home
- BTI vs VRTX Comparison
BTI vs VRTX Comparison
Compare BTI & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTI
- VRTX
- Stock Information
- Founded
- BTI 1902
- VRTX 1989
- Country
- BTI United Kingdom
- VRTX United States
- Employees
- BTI N/A
- VRTX N/A
- Industry
- BTI Medicinal Chemicals and Botanical Products
- VRTX EDP Services
- Sector
- BTI Health Care
- VRTX Technology
- Exchange
- BTI Nasdaq
- VRTX Nasdaq
- Market Cap
- BTI 119.8B
- VRTX 96.6B
- IPO Year
- BTI N/A
- VRTX 1991
- Fundamental
- Price
- BTI $51.96
- VRTX $410.82
- Analyst Decision
- BTI Strong Buy
- VRTX Buy
- Analyst Count
- BTI 3
- VRTX 25
- Target Price
- BTI $62.00
- VRTX $493.64
- AVG Volume (30 Days)
- BTI 4.0M
- VRTX 1.7M
- Earning Date
- BTI 02-12-2026
- VRTX 11-03-2025
- Dividend Yield
- BTI 5.85%
- VRTX N/A
- EPS Growth
- BTI N/A
- VRTX N/A
- EPS
- BTI 1.89
- VRTX 14.07
- Revenue
- BTI $35,067,817,512.00
- VRTX $11,418,800,000.00
- Revenue This Year
- BTI N/A
- VRTX $10.90
- Revenue Next Year
- BTI $3.10
- VRTX $9.57
- P/E Ratio
- BTI $27.56
- VRTX $29.16
- Revenue Growth
- BTI N/A
- VRTX 10.46
- 52 Week Low
- BTI $34.17
- VRTX $362.50
- 52 Week High
- BTI $59.29
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- BTI 36.46
- VRTX 61.10
- Support Level
- BTI $50.92
- VRTX $400.74
- Resistance Level
- BTI $53.18
- VRTX $411.91
- Average True Range (ATR)
- BTI 0.67
- VRTX 8.84
- MACD
- BTI -0.23
- VRTX 3.92
- Stochastic Oscillator
- BTI 22.05
- VRTX 97.78
About BTI British American Tobacco Industries p.l.c. ADR
The third-largest tobacco company by volume, British American Tobacco sold 518 billion cigarettes in 2024. Its leading brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans in cigarettes. Its ownership of the Camel, Natural American Spirit, and Newport brands are limited to the US. In next-generation products, the company has the Vuse brand in vaping, Glo in heated tobacco, and Velo in modern oral tobacco. The company also owns a 22.9% stake in ITC limited, the largest Indian cigarette company.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.